A Calibration Free Continuous Invasive Sensor Targeted at Glycaemic Control in the ICU

针对 ICU 血糖控制的免校准连续侵入式传感器

• 批准号: DT/F00267X/1
• 负责人: Tony James
• 金额: $ 31.51万
• 依托单位: University of Bath
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2007
• 资助国家: 英国
• 起止时间: 2007 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=DT%2FF00267X%2F1
• 关键词: Calibration; Free; Continuous; Invasive; Sensor

The development of an invasive fibre optic continuous glucose sensor/monitoring system is in direct response to the clinical need demonstrated by the seminal clinical study of Van Den Berghe et al. which was published in 2001. This study demonstrated that when the elevated glucose levels, usually experienced by Intensive Care Patients, were brought back and held within normal glucose levels by the continuous administration of insulin (Tight Glycaemic Control [TGC]), then patient mortality was reduced by 40% and morbidity by 37-46%. This reduction in morbidity was reflected in a reduction of the patient length of stay in the Intensive Care Unit thus providing additional economic benefits. The patient benefits described were achieved on the trial by intensively measuring and maintaining patient glucose levels intermittently-a maximum of hourly. Although the global ICU community have attempted to introduce TGC they have only introduced with relaxed limits (and hence achieved reduced benefits) because hourly monitoring of glucose in a typical ICU is not achievable and the fear is that during the blind interval between blood samples the adminstration of continuous insulin will push the patient into hypoglcaemia with catastrophic consequences. The development of an invasive continuous optical glucose sensor/monitor that provides real time data is aimed at enabling TGC and maximising patient and economic benefit. The development of a lifetime based system, that has a use model that is calibration free, will maximise market penetration and facilitate TGC benefits globally.

有创光纤连续葡萄糖传感器/监测系统的开发直接响应了货车Den Berghe等人在2001年发表的开创性临床研究所证明的临床需求。本研究表明，当通过持续给予胰岛素（严格血糖控制[TGC]）使重症监护患者通常经历的血糖水平升高恢复并保持在正常血糖水平时，患者死亡率降低40%，发病率降低37- 46%。发病率的降低反映在患者在重症监护室的住院时间缩短，从而提供了额外的经济效益。通过严格测量和维持患者血糖水平（最多每小时），在试验中实现了所述患者获益。尽管全球ICU社区已尝试引入TGC，但他们仅在放宽限制的情况下引入（因此获益减少），因为在典型的ICU中无法实现每小时血糖监测，并且担心在血液样本之间的盲期内，连续胰岛素给药将使患者陷入低血糖，并造成灾难性后果。提供真实的时间数据的侵入式连续光学葡萄糖传感器/监测器的开发旨在实现TGC并使患者和经济效益最大化。开发具有免校准使用模型的终身系统将最大限度地提高市场渗透率并促进TGC在全球范围内的利益。

项目成果

Biotinylated boronic acid fluorophore conjugates: Quencher elimination strategy for imaging and saccharide detection

生物素化硼酸荧光团缀合物：用于成像和糖检测的猝灭剂消除策略

• DOI: 10.1039/c2ra00542e
• 发表时间: 2012
• 期刊: RSC Advances
• 影响因子: 3.9
• 作者: D'Hooge F